重组变应原疫苗的策略及首批临床研究的丰硕成果。
Strategies for recombinant allergen vaccines and fruitful results from first clinical studies.
作者信息
Cromwell Oliver, Fiebig Helmut, Suck Roland, Kahlert Helga, Nandy Andreas, Kettner Jens, Narkus Annemie
机构信息
Research and Development, Allergopharma Joachim Ganzer KG, Hermann-Koerner-Strasse 52, D-21465 Reinbek, Germany.
出版信息
Immunol Allergy Clin North Am. 2006 May;26(2):261-81, vii. doi: 10.1016/j.iac.2006.02.001.
PMID:16701144
Abstract
Recombinant DNA technology has delivered the prospect of a new generation of preparations for allergen-specific immunotherapy. The first clinical studies with recombinant allergens have yielded encouraging results, suggesting that there is a good chance that such preparations will become available for use in the routine management of allergic disease.
摘要
重组DNA技术带来了新一代变应原特异性免疫疗法制剂的前景。首批使用重组变应原的临床研究已取得令人鼓舞的结果，这表明这类制剂很有可能会用于过敏性疾病的常规治疗。
Zotero 插件